February 21, 2017
Recommended Topic Related To:

Surfaxin

"The US Food and Drug Administration (FDA) has approved the first long-acting muscarinic antagonist/long-acting beta-2 agonist combination in a pressurized metered-dose inhaler (pMDI), using novel co-suspension technology for chronic obstructive p"...

A A A

Surfaxin




PATIENT INFORMATION

No information provided. Please refer to the WARNINGS AND PRECAUTIONS sections.

Last reviewed on RxList: 12/6/2016
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.